logo conference-reports

Conference Reports

При финансовой поддержке logo MSD Oncology

ESMO 2019 — Triple negative breast cancer: trilaciclib improves survival when given with gemcitabine+carboplatin

Surprise result from phase 2 trial comes despite lack of significant improvement on other endpoints.